Missionthemission Of Syneurx Is To Usea Humanistic Approach To Bring Breakthrough Therapeutics To Diseases And Conditions Wheretherearesignificant Unmet Needs Antiviral Platform Antiviral For Covid 19Currentlysyneurx Is Conducting Two Clinical Programs Of Covid 19 Treatmentsae Pentarlandiraas An Oral Capsuleand Airnecfluaas An Inhaled Treatmentthecompany S Covid 19 Efforts Began In February 2020 As Covid 19 Emerged To Bea Global Pandemicsyneurx Decided To Apply Its Extensiver&D Experiencewith Cns Therapeutics Toward R&D For Covid 19 Antivirals In An Effort To Help Develop A Safeeffectiveand Accessibletreatment That Would Prevent Theprogression And Transmission Of Thediseasesyneurx Scientists Arrived At Thetheory That Regulatory Enzymes Such As Proteasewould Bea Critically Important Ae Drug Targetfor Thesetypes Of Illnesseswhich Coincidentally Is Also A Target For Several Virally Caused Diseases Such As Hiv And Hepatitisresearchers Decided To Test Thecompany S Proprietary Library Of Compounds Against Theproteaseand Discovered That Thecompound That Becamepentarlandir Proved To Bethemost Safeand Efficacious In Preclinical Tests Pentarlandir S Ability To Block Coronavirus Replication Was Confirmed In Multiplerigorous Cellular Studies And It Was Also Proved To Maintain An Excellent Safety Profilewhich Madepentarlandir An Ideal Candidateto Go Into Clinical Developmentnmda Platform Modulation For Cns Disordersa New Perspectiveon Brain Function Modulationsyneurx Believes That Nmda Receptors Arethegrand Regulator Of Thebrainthereforesolutions To Thecurrent Unmet Needs In Many Central Nervous Systemcnsdisorders Need To Involvetherapies That Modulatenmda Receptor Functions
